肺
肺纤维化
特发性肺纤维化
医学
纳米复合材料
材料科学
纳米技术
病理
内科学
作者
Yuting Liu,Damin Xu,Xiaoyi Xing,Anqi Shen,Xinpeng Jin,Shijiao Li,Zhonghua Liu,Liming Wang,Yongwei Huang
出处
期刊:Nano Letters
[American Chemical Society]
日期:2024-09-27
标识
DOI:10.1021/acs.nanolett.4c04089
摘要
Idiopathic pulmonary fibrosis, an idiopathic interstitial lung disease with high mortality, remains challenging to treat due to the lack of clinically approved lung-targeting drugs. Herein, we present PDIC-DPC, a perylenediimide derivative that exhibits superior lung-selective enrichment. PDIC-DPC forms nanocomposites with plasma proteins, including fibrinogen beta chain and vitronectin, which bind to pulmonary endothelial receptors for lung-specific accumulation. Moreover, PDIC-DPC significantly suppresses transforming growth factor beta1 and activates adenosine monophosphate-activated protein kinase. As a result, compared to existing therapeutic drugs, PDIC-DPC achieves superior therapeutic outcomes, evidenced by the lowest Ashcroft score, significantly improved pulmonary function, and an extended survival rate in a bleomycin-induced pulmonary fibrosis model. This study elucidates the lung-selective enrichment of assembled prodrug from biological perspectives and affords a platform enabling therapeutic efficiency on idiopathic pulmonary fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI